Maxigen Biotech Inc. (TPE:1783)

Maxigen Biotech Revenue

Maxigen Biotech had revenue of 221.01M TWD in the quarter ending June 30, 2026, with 5.84% growth. This brings the company's total for the last twelve months to 837.44M, up 9.39% year-over-year. In the year 2025, Maxigen Biotech had annual revenue of 811.56M with 19.23% growth. That makes Maxigen Biotech the 32,330th largest company in the world by revenue and 1,660th in Taiwan.

• Revenue (ttm): 837.44M
• Revenue Growth: +9.39%
• P/S Ratio: 3.76
• Revenue / Employee: n/a
• Employees: n/a
• Market Cap: 3.15B

Revenue Chart

Chart

Chart

Revenue by Segment

By Segment

Chart

• Europe and America 328.86M 40.5%
• Taiwan 322.95M 39.8%
• Asia 154.27M 19.0%
• Other Regions 5.48M 0.7%

By Geography

Chart

• Europe and America 328.86M 40.5%
• Taiwan 322.95M 39.8%
• Asia 154.27M 19.0%
• Others 5.48M 0.7%

Fiscal year ended Dec 31, 2025 See the full Maxigen Biotech breakdown

Revenue History

Fiscal Year End	Revenue	Change	Growth
Dec 31, 2025	811.56M	130.91M	19.23%
Dec 31, 2024	680.65M	58.54M	9.41%
Dec 31, 2023	622.12M	17.68M	2.93%
Dec 31, 2022	604.43M	92.46M	18.06%
Dec 31, 2021	511.98M	54.29M	11.86%

Data Source: S&P Global Market Intelligence Last updated: Aug 12, 2026

Revenue data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Oct 28, 2026

Data Sources Report a data error